Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Gresham House and Gresham House Strategic make up

Thu, 10th Jun 2021 16:31

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Gresham House Strategic PLC - Largest shareholder Gresham House PLC withdraws requisition notice for general meeting issued last month, following discussions. Gresham House, a 23% shareholder, had wanted the immediate removal of David Potter as chair, rather than at GHS's annual general meeting, then scheduled for September. The AGM now will brought forward and held no later than July 26, at which Potter will retire. GHS is seeking a new chair, but if one is not found by the time of the AGM, then Non-Executive Director Helen Sinclair will act as interim chair. Senior Independent Director Ken Lever will lead a strategy review "with a view to determining the best means of maximising value for all shareholders". Also appoints Graham Bird as a non-independent non-executive director, effective immediately. Bird is chief financial officer of escape room chain Escape Hunt PLC and had previously been fund manager of GHS as an employee of Gresham House Asset Management Ltd.

----------

Kosmos Energy Ltd - oil and gas exploration and production along Atlantic Margins, including offshore Ghana and Equatorial Guinea and in the US Gulf of Mexico - Roy Franklin joins board from Wednesday. Franklin is chair of FTSE 250 energy services company John Wood Group PLC. He started his career at BP PLC and was chair of Premier Oil PLC until it was acquired by Chrysaor Holdings Ltd and relisted in London as Harbour Energy PLC.

----------

UniVision Engineering Ltd - Hong Kong-based supply, design, installation and maintenance of closed circuit television and surveillance systems - Edward Li resigns as director and will leave company "by mutual agreement" on July 1. Li was promoted to executive director only in June of last year. He was senior project manager for Univision's contract with the Hong Kong metro system and became projects director. UniVision is looking for a replacement.

----------

Arecor Therapeutics PLC - Saffron Walden, England-based biopharmaceuticals - Hires Lindsey Foulkes as chief operating officer. Foulkes was a consultant at McKinsey & Co and most recently was senior director of Business Development at Nasdaq-listed Liminal Biosciences Inc. Arecor debuted on AIM last week.

----------

Love Hemp Group PLC - London-based cannabidiol products maker - Hires James Martin as COO, effective immediately, charged with managing the company's growth strategy. Notes Martin has worked for Royal Dutch Shell PLC, Vodafone Group PLC, GlaxoSmithKline PLC, and accountants PwC. Also hires Anna Legge as chief communications officer and Martin Healy as chief growth officer. Legge was director of Communications at London-listed miner SolGold PLC. Love Hemp says Healy, previously head of Advertising Sales & Partnerships at Walt Disney Co, will work on international growth and commercial relationships, allowing Chief Commercial Officer Adam Pritchard to focus on the UK.

----------

Celtic PLC - Glasgow football club - Hires Ange Postecoglou as the club's first team manager, starting immediately. Postecoglou, a former manager of the Australian national team, replaces Neil Lennon, who resigned in February after Celtic failed to secure a record 10th consecutive Scottish Premiership title.

----------

BMO Managed Portfolio Trust PLC - invests in underlying investment companies for diversification - Hires Simon Longfellow as non-executive director, starting July 14. Longfellow was head of Investment Trust Marketing at Janus Henderson Investors.

----------

AEX Gold Inc - miner in Greenland - Line Frederiksen and David Neuhauser join board as non-executive directors following vote at AGM on Wednesday. Frederiksen is chief financial officer for Greenland-based telecom services provider Tele Greenland AS. Neuhauser is founder & managing director of hedge fund Livermore Partners in Chicago, a 6.0% shareholder in AEX Gold.

----------

Amati AIM VCT PLC - venture capital trust - Confirms Fiona Wollocombe as non-executive director, starting Thursday. Says Wollocombe has "extensive knowledge and experience in the VCT industry". Wollocombe is chair designate of Kings Arms Yard VCT PLC, Amati notes. As an executive, she worked in equity capital markets at NatWest Markets, part of NatWest Group PLC, and Deutsche Bank AG.

----------

N Brown Group PLC - Manchester-based online retailer - Confirms the appointment of Dominic Platt as independent non-executive director, starting immediately. Platt is CFO of BGL Group, a distributor of insurance and household financial services, having previously been finance director and managing director of international business at electricals retailer Darty PLC.

----------

Law Debenture Corp PLC - London-based investor and provider of pension and trust services - Hires Clare Askem as non-executive director, effective immediately. Askem also is non-executive director of homewares maker Portmeirion Group PLC and of Studio Retail Group PLC. Askem was managing director of Habitat at J Sainsbury PLC and also was an executive at Home Retail Group and Dixons Carphone PLC.

----------

Treatt PLC - Bury St Edmunds, Suffolk-based ingredients for food, beverage and fragrance - Non-Executive Director Richard Illek to step down from board on December 31, having served since June 2016.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.